A little over a week later, researchers conducting clinical trials in India reported good news: the Phase I trial had been a resounding success. Seventy-three of the eighty patients had excellent results across all parameters, demonstrating that the new drug had achieved its intended effect.
This made everyone in the institute very happy. After achieving such results in the first phase, things were basically set in stone. The remaining second and third phases were just a matter of increasing the number of participants. This also meant that the bonus was beckoning them.
Upon hearing this news, Si Mingyu and Li Zhenyuan both found it quite normal. Originally, this was a sure thing, and after more than three years of careful refinement, such a successful Phase I clinical trial was only natural.
This good news was also spread by several European and American patients who were accompanying them.
There are thousands of rare diseases, but the number of people suffering from them varies greatly, ranging from tens of thousands worldwide to over 100,000. As long as the number of people living within the official threshold is considered a rare disease, the new drug Li Zhenyuan is researching targets one of these diseases with a relatively high prevalence.
Of course, other pharmaceutical companies are also willing to prioritize research and development for rare diseases with large populations, after all, more consumers will buy them. However, new drug development doesn't guarantee results just because you invest money, so it's important to prioritize research and development with a high probability of success. After all, failure means nothing.
Patients in some countries have formed mutual aid organizations to encourage and help each other.
After receiving the news that a new drug had begun clinical trials, some people in the mutual aid organization followed in order to obtain first-hand information. After all, it was something that could save their lives, so it was worth paying attention to it.
These people weren't ordinary people; they all had connections, so it was hard for the clinical trial leader to stop them. Besides, there was nothing to stop them; they weren't causing trouble; they just wanted to know the progress every day.
But no matter what, this exciting good news inspired everyone.
Everyone knows that drugs for treating rare diseases are very expensive, but no matter how expensive the drugs are, there is always a price. If there are no drugs, even the rich will have money but nowhere to spend it.
Speaking of the wealthy, if someone with a serious illness could actually donate billions or even tens of billions of dollars to a pharmaceutical company to develop a cure for them, then they'd be fine. But again, just because you've invested doesn't guarantee success; it's perfectly normal for someone to die before a cure is developed.
This good news made some people who wanted to wait until the second phase of clinical trials no longer hesitate and immediately set off for India.
Indians can participate in the Phase II clinical trials, and they can too. Some people's illnesses can no longer be delayed. After all, the earlier the disease is treated, the better the effect.
If the success rate was the same as before, they would never dare to take the risk. Even if they didn't die on the spot, they would still suffer from severe sequelae, worse than death. But now, with a success rate of over 90% without any sequelae, it was worth the gamble. The 10% risk for saving their lives was not worth mentioning.
However, this clinical trial is not something that European and American patients can participate in just because they want to.
Some people may wonder, why can't I just come here and be your guinea pig?
no.
Because if an Indian has an accident during a clinical trial, it doesn't matter. As long as they get compensation, they have no worries, and the compensation is not much. But if you, a European or American, have an accident, not only will you have to pay a lot of money, but you may also be criticized by the media.
Those extreme human rights organizations or the seriously ill white leftists don't care whether it was voluntary or not, regardless of the circumstances or your purpose. They just ask if the person is dead. As long as they are dead, it is your responsibility.
As a medical research institute, I don't have the money to get into this trouble.
So a strange phenomenon emerged: these European and American patients tried every means to participate in clinical trials.
Patients participating in clinical trials receive no or reduced treatment fees, and some even pay outright. Disease is universal, and these patients naturally include both wealthy and ordinary people. Some are wealthy and can't wait for the new drug to officially launch, while others are ordinary people who wouldn't be able to afford it even if they knew it was on the market.
And you can't go to the person in charge of clinical trials here. His words don't count, and he has to get the boss's approval. After all, he can't afford the responsibility if something goes wrong.
And even if a rich person paid him to secretly arrange your admission, how could so many people turn a blind eye? Don't even think you could bribe everyone. If that were the case, there would be no such thing as "trade secrets" in the world.
So the matter was reported to Robert, the head of the Fifty State Federal Medical Research Institute branch, who then reported it to Li Zhenyuan.
Finally, Si Mingyu organized a video conference for the three of them.
"Mr. Robert, how do you usually solve this kind of problem?"
"It all depends on the pharmaceutical company's choice. As long as participants in clinical trials sign detailed legal documents and ultimately can't win a lawsuit in their own country, then there's no problem. Those white left idiots are everywhere, and they'll intervene and dictate everything." Robert is experienced in these matters. "If you don't want to go through all that trouble, just refuse those patients."
"What do those lunatics think has anything to do with me? Since they volunteered to participate in the clinical trial, we will strictly follow the regulations. Life and death are predestined, and wealth and honor are in the hands of God." How could Si Mingyu care about the thoughts of a group of foreign lunatics?
"Boss, then I know what to do. But I have another suggestion. We can provide tiered services to those rich people. The more they pay, the better treatment they can get. We can even let their personal doctors get involved. Of course, this is the part that will not disclose company secrets, such as routine physical examinations. This is not uncommon here." Robert suggested.
"That's a good idea. Let's do as you say. We can use a certain percentage of the extra income as bonuses for everyone, but we must strictly follow the prescribed procedures." Since everyone was doing this privately, he had nothing to worry about.
"Thank you, boss!" Robert was overjoyed.
Allowing the rich to spend money on extra treatment is a good thing for both parties: the rich increase the success rate of treatment, pharmaceutical companies get money, and everyone has a bright future.
Besides, the boss had promised an extra bonus. Although this was Robert's second time meeting his boss, judging by the funding he had given to the institute and the treatment of his employees in the past, he was definitely not a stingy person.
For those in the Fifty States, as long as they were paid enough, they would work tirelessly. They worked overtime and received overtime pay, so Robert took it for granted that the new drug was successfully developed ahead of schedule.
The next thing to do will be done according to the results of this discussion.
Continue read on readnovelmtl.com
